<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03594708</url>
  </required_header>
  <id_info>
    <org_study_id>UCS2018</org_study_id>
    <nct_id>NCT03594708</nct_id>
  </id_info>
  <brief_title>Immunonutrition in Ulcerative Colitis</brief_title>
  <official_title>Impact of Immunonutrition Supplementation Combining Fermentable Fiber, Omega-3 Fatty Acids, Vitamin D, Vitamin E, and Zinc on Intestinal Inflammation, Gut Microbial Activity, and Severity of Symptoms in Ulcerative Colitis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baptist Memorial Health Care Corporation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baptist Memorial Health Care Corporation</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study tests the hypothesis that a supplement that combines a functional fiber, long
      chain omega-3 polyunsaturated fatty acids (PUFAs), vitamin D3, vitamin E, and zinc will
      reduce clinical symptoms, decrease pro-inflammatory cytokines in the blood and ergo decrease
      inflammation, promote beneficial microbial activity in the colon, and help recovery of the
      intestinal mucosa of ulcerative colitis (UC) patients compared with a placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An anticipated 30 participants with newly diagnosed active ulcerative colitis will be
      recruited to participate in a randomized control trial, with 50% of the subjects distributed
      to the supplement (n=15) and the other 50% provided a placebo control (n=15). This is
      considered as a &quot;proof of concept&quot; study to determine if there is evidence that a
      multi-ingredient supplement (immunonutrition) will reduce UC disease severity.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">April 30, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduced inflammatory cytokines</measure>
    <time_frame>2 months</time_frame>
    <description>cytokines will be isolated from blood analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improved microbiome/ increased Short-Chain Fatty acid (SCFA) counts</measure>
    <time_frame>2 months</time_frame>
    <description>SCFA will be isolated from stool sample. SCFAs are anti-inflammatory components generated in the colon. The SCFAs looked at include acetate, lactate, propionate, butyrate, and isobutyrate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduced bowel movements per day</measure>
    <time_frame>2 months</time_frame>
    <description>Many with Ulcerative colitis can experience 10+ bowel movements per day. This intervention is aiming to reduce the total number of bowel movements per day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decreased intestinal cramping/ pain</measure>
    <time_frame>2 months</time_frame>
    <description>Many with ulcerative colitis experience constant intestinal cramping. This intervention is geared towards reducing pain and discomfort for the participants</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo consisting of rice starch, light olive oil, and vegetable oil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Supplement</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>active supplement consisting of a fermentable fiber, omega-3 polyunsaturated fatty acid, vitamin D3, vitamin E, and zinc</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Nutrition supplement</intervention_name>
    <description>Fermentable fiber, omega-3 fatty acid, vitamin D3, vitamin E, zinc</description>
    <arm_group_label>Supplement</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo supplement</intervention_name>
    <description>rice starch, light olive oil, vegetable oil</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with active ulcerative colitis (proof of diagnosis from gastroenterologist),
             over 18 years old, has over 50% gut remaining, fully connected bowels (no colostomy),
             currently on 5-aminosalicylates (ASA) drugs, not pregnant or lactating

        Exclusion Criteria:

        -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Randal K Buddington, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Memphis</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Katie E Cook, BA</last_name>
    <phone>612-804-5322</phone>
    <email>kecook1@memphis.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Randal K Buddington, PhD</last_name>
    <phone>662-418-2666</phone>
    <email>rbddngtn@memphis.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>GI Specialists Foundation</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Bierman, MD</last_name>
      <phone>901-761-3900</phone>
      <email>Paul.Bierman@bmg.md</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Torres MI, Rios A. Current view of the immunopathogenesis in inflammatory bowel disease and its implications for therapy. World J Gastroenterol. 2008 Apr 7;14(13):1972-80. Review.</citation>
    <PMID>18395894</PMID>
  </reference>
  <reference>
    <citation>Lewis JD, Abreu MT. Diet as a Trigger or Therapy for Inflammatory Bowel Diseases. Gastroenterology. 2017 Feb;152(2):398-414.e6. doi: 10.1053/j.gastro.2016.10.019. Epub 2016 Oct 25.</citation>
    <PMID>27793606</PMID>
  </reference>
  <reference>
    <citation>Ruemmele FM. Role of Diet in Inflammatory Bowel Disease. Ann Nutr Metab. 2016;68 Suppl 1:33-41. doi: 10.1159/000445392. Epub 2016 Jun 30. Review.</citation>
    <PMID>27355913</PMID>
  </reference>
  <reference>
    <citation>Rampertab S, Brown A. Inflammatory bowel disease. In: The Health Professional's Guide to Gastrointestinal Nutrition. Academy of Nutrition and Dietetics, 2015.</citation>
  </reference>
  <reference>
    <citation>Seidner DL, Lashner BA, Brzezinski A, Banks PL, Goldblum J, Fiocchi C, Katz J, Lichtenstein GR, Anton PA, Kam LY, Garleb KA, Demichele SJ. An oral supplement enriched with fish oil, soluble fiber, and antioxidants for corticosteroid sparing in ulcerative colitis: a randomized, controlled trial. Clin Gastroenterol Hepatol. 2005 Apr;3(4):358-69.</citation>
    <PMID>15822041</PMID>
  </reference>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>January 19, 2018</study_first_submitted>
  <study_first_submitted_qc>July 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 20, 2018</study_first_posted>
  <last_update_submitted>July 11, 2018</last_update_submitted>
  <last_update_submitted_qc>July 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baptist Memorial Health Care Corporation</investigator_affiliation>
    <investigator_full_name>Katherine Cook</investigator_full_name>
    <investigator_title>Research Assistant</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

